REG - Renalytix PLC - Issue of Shares

RenalytixAnnouncement

17/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230717:nRSQ1495Ga&default-theme=true

RNS Number : 1495G  Renalytix PLC  17 July 2023

Renalytix plc

("Renalytix" or the "Company")

 

Issue of Shares

 

LONDON and SALT LAKE CITY - July 17, 2023 - Renalytix plc
(http://www.renalytix.com) (NASDAQ: RNLX) (LSE: RENX), announces the repayment
of $1.06 million of the Company's convertible bond, further details of which
were announced on 31 March 2022. The repayment is being made through the issue
of 526,211 American Depositary Shares ("ADS").

 

After settlement of the repayment, the principal remaining under the
convertible bond will be reduced by $1.06 million to $16.96 million.

 

1,052,422 new ordinary shares of £0.0025 each in the capital of the Company
(the "Ordinary Shares") will be issued to settle the conversion of 526,211
ADSs, with each ADS representing two Ordinary Shares.

 

An application has been made to the London Stock Exchange for the new Ordinary
Shares to be admitted to trading on AIM. It is expected that admission of the
1,052,422 new Ordinary Shares to trading on AIM will become effective on, or
around, 8am UK time on 19 July 2023 ("Admission"). The new Ordinary Shares
will rank pari passu with the existing Ordinary Shares of the Company.

 

Total voting rights

Following Admission, the Company will have 94,833,900 Ordinary Shares in issue
with each share carrying the right to one vote. The Company has no Ordinary
Shares held in treasury. The total number of voting rights in the Company
following Admission will therefore be 94,833,900.

 

For further information, please contact:

 

 Renalytix plc                                                  www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                          Via Walbrook PR

 Stifel (Nominated Adviser, Joint Broker)                       Tel: 020 7710 7600
 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 Investec Bank plc (Joint Broker)                               Tel: 020 7597 4000
 Gary Clarence / Shalin Bhamra

 Walbrook PR Limited                                            Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                                                (http://renalytix@walbrookpr.com)
 Paul McManus / Lianne Applegarth / Alice Woodings              Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                                  Tel: 415-389-6400 or investors@renalytix.com (http://investors@renalytix.com)

 

 

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEGPUPAMUPWPGQ